Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME of [14C]-Ibrexafungerp in Healthy Males
NCT05668429Phase 1Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Dec 2022
- Primary completion
- Jan 2023
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrexafungerp in fungal infection, sponsored by SCYNEXIS, Inc. Primary endpoints: Mass balance recovery at Day 26, Metabolite identification in plasma, urine and faeces at Day 26 and 3 more. Started Dec 2022; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
fungal infection
Beyond the preview
Go deeper on NCT05668429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05668429.